Incidence, Management and Outcome of Hepatic Veno-Occlusive Disease /Sinusoidal Obstruction Syndrome After Hematopoietic Stem Cell Transplant in Thalassemia Major Patients: A Prospective Study of Pakistani BMT

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2024 Feb 15

PMID 38356807

Authors

Haider Nisar

Memoona Khan

Tariq Azam Khattak

Tariq Ghafoor

Qamar Un Nisa Chaudhry

Affiliations

Soon will be listed here.

Abstract

Objectives: Hepatic Veno occlusive disease (VOD), also known as sinusoidal obstruction syndrome (VOD/SOS), is a post-transplant life threatening complication. In this study, we aimed to discuss the incidence, management and outcome of VOD in post allogenic transplant patients of beta thalassemia major (BTM).

Methods: A prospective study was conducted in Armed Forces Bone Marrow Transplant Center, between 2001-2022. A total of 385 fully Human Leucocyte Antigen (HLA) matched BTM patients, with Ursodeoxycholic acid for prophylaxis, were included in the study. Incidence of VOD was calculated through cumulative incidence estimates. Chi square test and Mann Whitney test were used to compare discrete and continuous variables respectively. VOD was diagnosed and graded according to European Society for Blood and Marrow Transplantation EBMT Pediatric diagnostic criteria. Risk factors for VOD were grouped as recipient, transplant and donor related. Univariate analysis was performed by log-rank test. All patients who developed VOD were managed primarily with fluid restriction and strict input output monitoring. Statistical analyses were performed using SPSS v 25.0.

Results: Out of 385 transplant patients, forty developed VOD. Median time from date of transplant till onset of VOD was 14 days (range 6-30). Cumulative incidence of all grade VOD was 10.39% (95% CI, 7-14). Eleven out of 40 patients who developed VOD died. Cumulative incidence of Transplant related mortality (TRM) for patients with and VOD was 20.5% (95% CI, 16.6-25.1) vs 27.5% (95% CI, 16.1-42) (p value 0.318) respectively. Among risk factors, age of recipient and fibrosis (p value of 0.04 and 0.000 respectively) were found to be significantly associated with VOD.

Conclusions: Careful selection of transplant candidates before transplant can help reduce the incidence of VOD.

References

Chopra R, Eaton J, Grassi A, Potter M, Shaw B, Salat C . Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2001; 111(4):1122-9. DOI: 10.1046/j.1365-2141.2000.02475.x. View

Shenoy S, Walters M, Ngwube A, Soni S, Jacobsohn D, Chaudhury S . Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. Biol Blood Marrow Transplant. 2018; 24(6):1216-1222. PMC: 5993578. DOI: 10.1016/j.bbmt.2018.01.023. View

Coppell J, Richardson P, Soiffer R, Martin P, Kernan N, Chen A . Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2009; 16(2):157-68. PMC: 3018714. DOI: 10.1016/j.bbmt.2009.08.024. View

Carreras E, Diaz-Beya M, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M . The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011; 17(11):1713-20. DOI: 10.1016/j.bbmt.2011.06.006. View

Bajwa R, Mahadeo K, Taragin B, Dvorak C, McArthur J, Jeyapalan A . Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and.... Biol Blood Marrow Transplant. 2017; 23(11):1817-1825. DOI: 10.1016/j.bbmt.2017.07.021. View

Sabloff M, Chandy M, Wang Z, Logan B, Ghavamzadeh A, Li C . HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2010; 117(5):1745-50. PMC: 3056598. DOI: 10.1182/blood-2010-09-306829. View

Hashmi K, Khan B, Ahmed P, Hussain I, Rasul S, Hanif E . Allogeneic bone marrow transplantation in beta-thalassaemia--single centre study. J Pak Med Assoc. 2004; 54(10):499-503. View

Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws H, Dilloo D . Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2003; 33(2):189-95. DOI: 10.1038/sj.bmt.1704329. View

Cappelli B, Chiesa R, Evangelio C, Biffi A, Roccia T, Frugnoli I . Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol. 2009; 147(4):554-60. DOI: 10.1111/j.1365-2141.2009.07871.x. View

10.

Ullah K, Ahmed P, Raza S, Satti T, Nisa Q, Mirza S . Allogeneic stem cell transplantation in hematological disorders: single center experience from Pakistan. Transplant Proc. 2007; 39(10):3347-57. DOI: 10.1016/j.transproceed.2007.08.099. View

11.

Mahadeo K, Bajwa R, Abdel-Azim H, Lehmann L, Duncan C, Zantek N . Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2019; 7(1):e61-e72. DOI: 10.1016/S2352-3026(19)30201-7. View

12.

Akhtar I, Ashraf M, Khalid I, Hussain M . Surgical outcome of spelenectomy in Thalassemia major in children. Pak J Med Sci. 2016; 32(2):305-8. PMC: 4859011. DOI: 10.12669/pjms.322.8815. View

13.

Ahmed S, Ayub M, Naeem M, Nazir F, Hussain A, Ghilzai D . Thalassemia Patients from Baluchistan in Pakistan Are Infected with Multiple Hepatitis B or C Virus Strains. Am J Trop Med Hyg. 2021; 104(4):1569-1576. PMC: 8045631. DOI: 10.4269/ajtmh.20-0740. View

14.

Cairo M, Cooke K, Lazarus H, Chao N . Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. Br J Haematol. 2020; 190(6):822-836. PMC: 7483983. DOI: 10.1111/bjh.16557. View

15.

McDonald G, Sharma P, Matthews D, Shulman H, Thomas E . Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984; 4(1):116-22. DOI: 10.1002/hep.1840040121. View

16.

Cheuk D, Wang P, Lee T, Chiang A, Ha S, Lau Y . Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007; 40(10):935-44. DOI: 10.1038/sj.bmt.1705835. View

17.

Strouse C, Zhang Y, Zhang M, DiGilio A, Pasquini M, Horowitz M . Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2018; 24(10):2072-2080. PMC: 6239945. DOI: 10.1016/j.bbmt.2018.06.013. View

18.

Roeker L, Kim H, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J . Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018; 25(1):137-144. DOI: 10.1016/j.bbmt.2018.07.039. View

19.

Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle J . Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2017; 53(2):138-145. PMC: 5803572. DOI: 10.1038/bmt.2017.161. View

20.

Bulley S, Strahm B, Doyle J, Dupuis L . Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer. 2006; 48(7):700-4. DOI: 10.1002/pbc.20934. View